U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07466251) titled 'PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke' on March 07.
Brief Summary: This study is a prospective, multicenter, double-blind, randomized, placebo-controlled clinical trial designed to evaluate whether early administration of PCSK9 inhibitors can effectively improve functional outcomes at 90 days in patients with ischemic stroke (AIS) associated with intracranial atherosclerotic stenosis (ICAS), primarily assessed using the modified Rankin Scale at 90 days.
Study Start Date: Sept. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Acute Ischemic Stroke AIS
Intracranial Atherosclerosis ICAS
Ather...